HomeCompareVMGRX vs CL

VMGRX vs CL: Dividend Comparison 2026

VMGRX yields 20.12% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMGRX wins by $32.6K in total portfolio value
10 years
VMGRX
VMGRX
● Live price
20.12%
Share price
$21.92
Annual div
$4.41
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73.5K
Annual income
$6,822.98
Full VMGRX calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — VMGRX vs CL

📍 VMGRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMGRXCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMGRX + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMGRX pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMGRX
Annual income on $10K today (after 15% tax)
$1,709.88/yr
After 10yr DRIP, annual income (after tax)
$5,799.53/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, VMGRX beats the other by $1,165.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMGRX + CL for your $10,000?

VMGRX: 50%CL: 50%
100% CL50/50100% VMGRX
Portfolio after 10yr
$57.3K
Annual income
$6,137.34/yr
Blended yield
10.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

VMGRX
No analyst data
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMGRX buys
0
CL buys
9
PoliticianChamberTickerTypeAmountDate
John Boozman🏛 Senate$CL▼ Sell$1,001 - $15,0002025-10-09
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-10-07
Rick Larsen🏢 House$CL▼ Sell$1,001 - $15,0002025-10-06
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-09-29
Julie Johnson🏢 House$CL▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CL▼ Sell$1,001 - $15,0002025-09-11
Tim Moore🏢 House$CL▼ Sell$1,001 - $15,0002025-09-10
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-08-26
Lisa McClain🏢 House$CL▲ Buy$1,001 - $15,0002025-08-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMGRXCL
Forward yield20.12%2.44%
Annual dividend / share$4.41$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$73.5K$41.0K
Annual income after 10y$6,822.98$5,451.69
Total dividends collected$41.9K$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: VMGRX vs CL ($10,000, DRIP)

YearVMGRX PortfolioVMGRX Income/yrCL PortfolioCL Income/yrGap
1← crossover$12,712$2,011.63$11,014$313.84+$1.7KVMGRX
2$15,991$2,389.82$12,200$415.44+$3.8KVMGRX
3$19,920$2,809.72$13,607$553.09+$6.3KVMGRX
4$24,586$3,271.10$15,301$741.41+$9.3KVMGRX
5$30,080$3,773.10$17,374$1,002.00+$12.7KVMGRX
6$36,500$4,314.27$19,958$1,367.44+$16.5KVMGRX
7$43,947$4,892.57$23,243$1,887.87+$20.7KVMGRX
8$52,529$5,505.48$27,512$2,642.43+$25.0KVMGRX
9$62,356$6,150.05$33,197$3,759.22+$29.2KVMGRX
10$73,544$6,822.98$40,973$5,451.69+$32.6KVMGRX

VMGRX vs CL: Complete Analysis 2026

VMGRXStock

This actively managed, mid-capitalization option invests primarily in the stocks of mid-size domestic companies that the fund’s investment managers believe have stronger earnings and revenue growth prospects than the average mid-cap company. Investors who are seeking exposure to the mid-cap arena of the U.S. stock market and who are willing to endure the volatility that can come from an investment in stocks may wish to consider this fund as an option for their portfolio.The Vanguard Mid-Cap Growth Fund changed investment managers on November 17, 2025. This may result in capital gains distributions, which could be taxable if you hold shares in a regular (taxable) account. Vanguard provides monthly updates on estimated realized and unrealized gains in the "Distributions" section of the fund’s website page.The expense ratio for Mid-Cap Growth Fund will increase from 33bps to 39bps, with a 5bp fee waiver, making the effective expense ratio 34bps.

Full VMGRX Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this VMGRX vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMGRX vs SCHDVMGRX vs JEPIVMGRX vs OVMGRX vs KOVMGRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.